- Home
- MLKN vs ARVN Comparison
MLKN vs ARVN Comparison
Compare MLKN & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLKN
- ARVN
- Stock Information
- Founded
- MLKN 1905
- ARVN 2015
- Country
- MLKN United States
- ARVN United States
- Employees
- MLKN N/A
- ARVN N/A
- Industry
- MLKN Office Equipment/Supplies/Services
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- MLKN Consumer Discretionary
- ARVN Health Care
- Exchange
- MLKN Nasdaq
- ARVN Nasdaq
- Market Cap
- MLKN 1.5B
- ARVN 1.2B
- IPO Year
- MLKN N/A
- ARVN 2018
- Fundamental
- Price
- MLKN $19.20
- ARVN $7.03
- Analyst Decision
- MLKN
- ARVN Buy
- Analyst Count
- MLKN 0
- ARVN 13
- Target Price
- MLKN N/A
- ARVN $34.42
- AVG Volume (30 Days)
- MLKN 705.9K
- ARVN 3.5M
- Earning Date
- MLKN 03-26-2025
- ARVN 05-06-2025
- Dividend Yield
- MLKN 3.91%
- ARVN N/A
- EPS Growth
- MLKN N/A
- ARVN N/A
- EPS
- MLKN 0.43
- ARVN N/A
- Revenue
- MLKN $3,597,000,000.00
- ARVN $263,399,999.00
- Revenue This Year
- MLKN $4.29
- ARVN N/A
- Revenue Next Year
- MLKN $4.62
- ARVN $7.99
- P/E Ratio
- MLKN $45.11
- ARVN N/A
- Revenue Growth
- MLKN N/A
- ARVN 235.54
- 52 Week Low
- MLKN $17.83
- ARVN $6.85
- 52 Week High
- MLKN $31.73
- ARVN $40.16
- Technical
- Relative Strength Index (RSI)
- MLKN 43.55
- ARVN 23.59
- Support Level
- MLKN $17.83
- ARVN $8.51
- Resistance Level
- MLKN $20.64
- ARVN $9.17
- Average True Range (ATR)
- MLKN 0.62
- ARVN 0.51
- MACD
- MLKN 0.12
- ARVN -0.01
- Stochastic Oscillator
- MLKN 48.75
- ARVN 6.84
About MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract , International Contract & Specialty International & Specialty and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.